

## AmeriHealth Caritas Louisiana

<b>*National Imaging Associates, Inc.*</b>	
<b>Clinical guidelines</b> <b>CHEST (Thorax) CT</b>	<b>Original Date: September 1997</b>
<b>CPT Codes: 71250, 71260, 71270, 71271</b>	<b>Last Revised Date: <del>March 2022</del> May 2023</b>
<b>Guideline Number: NIA_CG_020</b>	<b>Implementation Date: January 2023<del>4</del></b>

### GENERAL INFORMATION

- It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

This Chest CT Guideline covers CPT codes 71250 (CT chest without contrast), CT chest with contrast (71260), CT chest without and with contrast (71270) and Low dose CT scan (LDCT) for lung cancer screening (71271). **When the case is listed as CT chest in BBI and the clinical scenario or request for LDCT in the office notes meets appropriate use criteria for a LDCT, the LDCT is approvable due to these overlapping CPT codes. Reprocessing of the case to a separate LDCT request is not required.**

### INDICATIONS FOR CHEST CT

#### For Annual Lung Cancer Screening

The use of low-dose, non-contrast spiral (helical) multi-detector CT imaging as an annual screening technique for lung cancer is considered **medically necessary ONLY** when used to screen for lung cancer for certain high-risk **asymptomatic** individuals when **ALL** of the following criteria are met<sup>1</sup>:

#### Group 1:

~~\*National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.~~

- Individual is between 50-80 years of age;<sup>\*</sup> **AND**
- There is at least a 20 pack-year history of cigarette<sup>\*\*</sup> smoking; **AND**
- If the individual is a former smoker, that individual had quit smoking within the previous 15 years.

**\*May approve for individuals over the age limit if the individual is a candidate for and willing to undergo curative treatment**

**\*\* Annual screening refers to the use of cigarettes only; does not take other forms of smoking into the calculation (i.e., vaping, pipe, cigar, marijuana)**

#### **Group 2:**

**Yearly Low-Dose CT surveillance after completion of definitive treatment of non-small cell lung cancer as per these parameters:**

- **Stage I-II (treated with surgery +/- chemotherapy) starts at year 2-3 of surveillance**
- **Stage I-II (treated primarily with radiation) or stage III-IV with all sites treated with definitive intent starts at year 5 of surveillance**

#### **Nodule on Initial LDCT<sup>22</sup>**

- If multiple nodules, the largest and type is used for decision
- Follow-up with LDCT as per Lung-Rads criteria<sup>3,43,4</sup> (**Table 1**)

**Table 1: Lung-RADS® Assessment Categories<sup>5</sup>**

---

Category Descriptor	Lung-RADS Score	Findings	Management
<b>Incomplete</b>	<b>0</b>	Prior chest CT examination(s) being located for comparison Part or all of lungs cannot be evaluated	Additional lung cancer screening CT images and/or comparison to prior chest CT examinations is needed
<b>Negative</b> No nodules and definitely benign nodules	<b>1</b>	No lung nodules Nodule(s) with specific calcifications: complete, central, popcorn, concentric rings and fat containing nodules	Continue annual screening with LDCT in 12 months
<b>Benign Appearance or Behavior</b> Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth	<b>2</b>	<b>Perifissural nodule(s)</b> (See Footnote 11) < 10 mm (524 mm <sup>3</sup> )	
		<b>Solid nodule(s):</b> < 6 mm (< 113 mm <sup>3</sup> ) new < 4 mm (< 34 mm <sup>3</sup> )	
		<b>Part solid nodule(s):</b> < 6 mm total diameter (< 113 mm <sup>3</sup> ) on baseline screening	
		<b>Non solid nodule(s) (GGN):</b> <30 mm (<14137 mm <sup>3</sup> ) OR ≥ 30 mm (≥ 14137 mm <sup>3</sup> ) and unchanged or slowly growing	
<b>Probably Benign</b> Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer	<b>3</b>	<b>Category 3 or 4 nodules unchanged for ≥ 3 months</b>	6 month LDCT
		<b>Solid nodule(s):</b> ≥ 6 to < 8 mm (≥ 113 to < 268 mm <sup>3</sup> ) at baseline OR new 4 mm to < 6 mm (34 to < 113 mm <sup>3</sup> )	
		<b>Part solid nodule(s)</b> ≥ 6 mm total diameter (≥ 113 mm <sup>3</sup> ) with solid component < 6 mm (< 113 mm <sup>3</sup> ) OR new < 6 mm total diameter (< 113 mm <sup>3</sup> )	
<b>Suspicious</b> Findings for which additional diagnostic testing is recommended	<b>4A</b>	<b>Non solid nodule(s)</b> (GGN) ≥ 30 mm (≥ 14137 mm <sup>3</sup> ) on baseline CT or new	3 month LDCT; PET/CT may be used when there is a ≥ 8 mm (≥ 268 mm <sup>3</sup> ) solid component
		<b>Solid nodule(s):</b> ≥ 8 to < 15 mm (≥ 268 to < 1767 mm <sup>3</sup> ) at baseline OR growing < 8 mm (< 268 mm <sup>3</sup> ) OR new 6 to < 8 mm (113 to < 268 mm <sup>3</sup> )	
		<b>Part solid nodule(s):</b> ≥ 6 mm (≥ 113 mm <sup>3</sup> ) with solid component ≥ 6 mm to < 8 mm (≥ 113 to < 268 mm <sup>3</sup> ) OR with a new or growing < 4 mm (< 34 mm <sup>3</sup> ) solid component	
<b>Very Suspicious</b> Findings for which additional diagnostic testing and/or tissue sampling is recommended	<b>4B</b>	<b>Endobronchial nodule</b>	Chest CT with or without contrast, PET/CT and/or tissue sampling depending on the *probability of malignancy and comorbidities. PET/CT may be used when there is a ≥ 8 mm (≥ 268 mm <sup>3</sup> ) solid component. For new large nodules that develop on an annual repeat screening CT, a 1 month LDCT may be recommended to address potentially infectious or inflammatory conditions
		<b>Solid nodule(s)</b> ≥ 15 mm (≥ 1767 mm <sup>3</sup> ) OR new or growing, and ≥ 8 mm (≥ 268 mm <sup>3</sup> )	
	<b>4X</b>	<b>Part solid nodule(s) with:</b> a solid component ≥ 8 mm (≥ 268 mm <sup>3</sup> ) OR a new or growing ≥ 4 mm (≥ 34 mm <sup>3</sup> ) solid component	
<b>Other</b> Clinically Significant or Potentially Clinically Significant Findings (non lung cancer)	<b>S</b>	<b>Modifier - may add on to category 0-4 coding</b>	As appropriate to the specific finding

## **Incidental Lung Nodules<sup>6</sup>**

~~Incidental pulmonary nodules detected on a nonscreening~~

**Table 1: Lung-RADS® Assessment Categories<sup>5</sup>**

Category Descriptor	Lung-RADS Score	Findings	Management
<b>Incomplete</b>	<b>0</b>	Prior chest CT examination(s) being located for comparison Part or all of lungs cannot be evaluated	Additional lung cancer screening CT images and/or comparison to prior chest CT examinations is needed
<b>Negative</b> No nodules and definitely benign nodules	<b>1</b>	No lung nodules Nodule(s) with specific calcifications: complete, central, popcorn, concentric rings and fat containing nodules	Continue annual screening with LDCT in 12 months
<b>Benign Appearance or Behavior</b> Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth	<b>2</b>	<b>Perifissural nodule(s)</b> (See Footnote 11) < 10 mm (524 mm <sup>3</sup> )	
		<b>Solid nodule(s):</b> < 6 mm (< 113 mm <sup>3</sup> ) new < 4 mm (< 34 mm <sup>3</sup> )	
		<b>Part solid nodule(s):</b> < 6 mm total diameter (< 113 mm <sup>3</sup> ) on baseline screening	
		<b>Non solid nodule(s) (GGN):</b> <30 mm (<14137 mm <sup>3</sup> ) <b>OR</b> ≥ 30 mm (≥ 14137 mm <sup>3</sup> ) and unchanged or slowly growing <b>Category 3 or 4 nodules unchanged for ≥ 3 months</b>	
<b>Probably Benign</b> Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer	<b>3</b>	<b>Solid nodule(s):</b> ≥ 6 to < 8 mm (≥ 113 to < 268 mm <sup>3</sup> ) at baseline <b>OR</b> new 4 mm to < 6 mm (34 to < 113 mm <sup>3</sup> ) <b>Part solid nodule(s)</b> ≥ 6 mm total diameter (≥ 113 mm <sup>3</sup> ) with solid component < 6 mm (< 113 mm <sup>3</sup> ) <b>OR</b> new < 6 mm total diameter (< 113 mm <sup>3</sup> ) <b>Non solid nodule(s)</b> (GGN) ≥ 30 mm (≥ 14137 mm <sup>3</sup> ) on baseline CT or new	6 month LDCT
<b>Suspicious</b> Findings for which additional diagnostic testing is recommended	<b>4A</b>	<b>Solid nodule(s):</b> ≥ 8 to < 15 mm (≥ 268 to < 1767 mm <sup>3</sup> ) at baseline <b>OR</b> growing < 8 mm (< 268 mm <sup>3</sup> ) <b>OR</b> new 6 to < 8 mm (113 to < 268 mm <sup>3</sup> ) <b>Part solid nodule(s):</b> ≥ 6 mm (≥ 113 mm <sup>3</sup> ) with solid component ≥ 6 mm to < 8 mm (≥ 113 to < 268 mm <sup>3</sup> ) <b>OR</b> with a new or growing < 4 mm (< 34 mm <sup>3</sup> ) solid component <b>Endobronchial nodule</b>	3 month LDCT; PET/CT may be used when there is a ≥ 8 mm (≥ 268 mm <sup>3</sup> ) solid component
<b>Very Suspicious</b> Findings for which additional diagnostic testing and/or tissue sampling is recommended	<b>4B</b>	<b>Solid nodule(s)</b> ≥ 15 mm (≥ 1767 mm <sup>3</sup> ) <b>OR</b> new or growing, and ≥ 8 mm (≥ 268 mm <sup>3</sup> ) <b>Part solid nodule(s) with:</b> a solid component ≥ 8 mm (≥ 268 mm <sup>3</sup> ) <b>OR</b> a new or growing ≥ 4 mm (≥ 34 mm <sup>3</sup> ) solid component	Chest CT with or without contrast, PET/CT and/or tissue sampling depending on the "probability of malignancy and comorbidities. PET/CT may be used when there is a ≥ 8 mm (≥ 268 mm <sup>3</sup> ) solid component. <i>For new large nodules that develop on an annual repeat screening CT, a 1 month LDCT may be recommended to address potentially infectious or inflammatory conditions</i>
	<b>4X</b>	Category 3 or 4 nodules with additional features or imaging findings that increases the suspicion of malignancy	
<b>Other</b> Clinically Significant or Potentially Clinically Significant Findings (non lung cancer)	<b>S</b>	<b>Modifier - may add on to category 0-4 coding</b>	As appropriate to the specific finding

## Incidental Lung Nodules<sup>6</sup>

- Incidental pulmonary nodules detected on a non-screening (regular) Chest CT (use Fleischner Table)

- Age ≥ 35 years old – use Fleischner Table 2: Fleischner table
  - **Excludes**
    - Lung cancer screening (see lung cancer screeninglung cancer screening/LDCT guidelines above)
    - History of primary cancer (imaging follow-up for surveillance is 3 months to detect interval nodule growth)
    - Immunosuppression (may require a shorter follow-up, such as 1 month, if suspicion of fulminant infection)

**Note:** These should not be ordered as Low Dose CT

- **Incidental pulmonary nodules on non-chest CT (such as a shoulder CT or abdomen CT)**
  - Nodules > 8mm or those with very suspicious features need further Chest CT as early as possible
  - Nodules ≤ 8mm should follow the Fleischner table

**Incidental pulmonary nodules on ~~chest x-ray~~X-rays including portions of the chest (i.e., chest, ribs, shoulder, abdomen)** that are indeterminate (not typical of granulomatous disease) as noted by the radiologist. No time delay between the ~~chest~~ x-ray and the subsequent Chest CT needed).

**Table 2: 2017 Fleischner Society Guidelines for Management of Incidentally Detected Pulmonary Nodules<sup>6</sup>**

A: Solid Nodules*				
Nodule Type	Nodules <6 mm (<100 mm <sup>3</sup> )	Nodules 6–8 mm (100–250 mm <sup>3</sup> )	Nodules >8 mm (>250 mm <sup>3</sup> )	Comments
Single				
Low risk	No routine follow-up	CT at 6–12 mo, then consider CT at 18–24 mo	Consider CT at 3 mo, PET/CT, or tissue sampling	Nodules <6 mm do not require routine follow-up in low-risk patients (recommendation 1A)
High risk	Optional CT at 12 mo	CT at 6–12 mo, then at 18–24 mo	Consider CT at 3 mo, PET/CT, or tissue sampling	Certain patients at high risk with suspicious nodule morphology, upper lobe location, or both may warrant 12-mo follow-up (recommendation 1A)
Multiple				
Low risk	No routine follow-up	CT at 3–6 mo, then consider CT at 18–24 mo	CT at 3–6 mo, then consider CT at 18–24 mo	Use most suspicious nodule as guide to management; follow-up intervals may vary according to size and risk (recommendation 2A)
High risk	Optional CT at 12 mo	CT at 3–6 mo, then at 18–24 mo	CT at 3–6 mo, then at 18–24 mo	Use most suspicious nodule as guide to management; follow-up intervals may vary according to size and risk (recommendation 2A)
B: Subsolid Nodules*				
Nodule Type	Nodules <6 mm (<100 mm <sup>3</sup> )	Nodules ≥6 mm (≥100 mm <sup>3</sup> )	Comments	
Single				
Ground glass	No routine follow-up	CT at 6–12 mo to confirm persistence, then CT every 2 y until 5 y	For certain suspicious nodules <6 mm, consider follow-up at 2 y and 4 y; if solid component(s) develops or growth occurs, consider resection (recommendations 3A and 4A)	
Partly solid	No routine follow-up	CT at 3–6 mo to confirm persistence; if lesion is unchanged and solid component remains <6 mm, annual CT should be performed for 5 y	In practice, partly solid nodules cannot be defined as such until they are ≥6 mm, and nodules <6 mm usually do not require follow-up; persistent partly solid nodules with a solid component ≥6 mm should be considered highly suspicious (recommendations 4A–4C)	
Multiple	CT at 3–6 mo; if lesion is stable, consider CT at 2 y and 4 y	CT at 3–6 mo; subsequent management based on the most suspicious nodule(s)	Multiple <6-mm pure GGNs <sup>†</sup> usually are benign, but consider follow-up at 2 y and 4 y in select patients at high risk (recommendation 5A)	

### Known Cancer<sup>7–9</sup>

- For follow-up intervals for malignancies<sup>10</sup>



**Table 2: 2017 Fleischner Society Guidelines for Management of Incidentally Detected Pulmonary Nodules<sup>7</sup>**

A: Solid Nodules*				
Nodule Type	Size			Comments
	<6 mm (<100 mm³)	6–8 mm (100–250 mm³)	>8 mm (>250 mm³)	
Single				
Low risk†	No routine follow-up	CT at 6–12 months, then consider CT at 18–24 months	Consider CT at 3 months, PET/CT, or tissue sampling	Nodules <6 mm do not require routine follow-up in low-risk patients (recommendation 1A).
High risk†	Optional CT at 12 months	CT at 6–12 months, then CT at 18–24 months	Consider CT at 3 months, PET/CT, or tissue sampling	Certain patients at high risk with suspicious nodule morphology, upper lobe location, or both may warrant 12-month follow-up (recommendation 1A).
Multiple				
Low risk†	No routine follow-up	CT at 3–6 months, then consider CT at 18–24 months	CT at 3–6 months, then consider CT at 18–24 months	Use most suspicious nodule as guide to management. Follow-up intervals may vary according to size and risk (recommendation 2A).
High risk†	Optional CT at 12 months	CT at 3–6 months, then at 18–24 months	CT at 3–6 months, then at 18–24 months	Use most suspicious nodule as guide to management. Follow-up intervals may vary according to size and risk (recommendation 2A).
B: Subsolid Nodules*				
Nodule Type	Size			Comments
	<6 mm (<100 mm³)	≥6 mm (>100 mm³)		
Single				
Ground glass	No routine follow-up	CT at 6–12 months to confirm persistence, then CT every 2 years until 5 years		In certain suspicious nodules < 6 mm, consider follow-up at 2 and 4 years. If solid component(s) or growth develops, consider resection. (Recommendations 3A and 4A).
Part solid	No routine follow-up	CT at 3–6 months to confirm persistence. If unchanged and solid component remains <6 mm, annual CT should be performed for 5 years.		In practice, part-solid nodules cannot be defined as such until ≥6 mm, and nodules <6 mm do not usually require follow-up. Persistent part-solid nodules with solid components ≥6 mm should be considered highly suspicious (recommendations 4A–4C).
Multiple	CT at 3–6 months. If stable, consider CT at 2 and 4 years.	CT at 3–6 months. Subsequent management based on the most suspicious nodule(s).		Multiple <6 mm pure ground-glass nodules are usually benign, but consider follow-up in selected patients at high risk at 2 and 4 years (recommendation 5A).

### **Known Cancer<sup>8-10</sup>**

- Cancer staging (includes unknown primary)
- Cancer restaging
- Suspicious signs or symptoms of recurrence
- ~~Suspected cancer based on prior imaging<sup>11</sup>~~

### **Chest Mass (non-lung parenchymal)<sup>12</sup>**

(Preference should be given to MRI over chest CT for chest wall mass)

- Suspected cancer based on prior imaging<sup>11</sup>



- In a patient undergoing active treatment within the past year or as per surveillance imaging guidance for that cancer

### Chest Mass (non-lung parenchymal)<sup>12</sup>

- Mass or lesion, including lymphadenopathy, after ~~non-diagnostic/inconclusive~~ initial imaging; can allow one follow-up to ensure stability/benignity (additional follow up may be approved as needed if a bothersome change in the findings or symptoms persist post treatment)
- ~~Thymoma screening in Myasthenia Gravis patients<sup>13</sup>~~

### Interstitial Lung Disease<sup>14,15</sup>

- ~~Suspected or known~~ Thymoma screening in Myasthenia Gravis patients<sup>13</sup>

Known or Suspected Interstitial Lung Disease (often requested as high resolution CT) after initial chest x-ray excludes a more acute disease as the etiology for the concern, if clinically appropriate (if no concern for acute process recent CXR is not an absolute requirement)

- Based on restrictive pattern pulmonary function test ~~or signs or symptoms after initial chest x-ray~~
- In patients with known collagen vascular disease in whom ILD is suspected
- With signs or symptoms unresponsive to treatment such as:
  - Shortness of breath
  - Persistent dyspnea
  - Persistent cough
- Monitoring treatment response of known interstitial lung disease
- ~~Patients with known collagen vascular disease<sup>16</sup>~~
- ~~Guidance in selection of the most appropriate site for biopsy of diffuse lung disease<sup>17</sup>~~
- Guidance in selection of the most appropriate site for biopsy of diffuse lung disease<sup>14</sup>

### **Chronic Cough (> 8 weeks) and chest x-ray completed<sup>185</sup>**

- After evaluation for other causes and failed treatment for those diagnosed with:
  - Asthma
  - Gastroesophageal Reflux Disease
  - Discontinuation of ACE inhibitors
  - Postnasal drip
- Clinical concern for bronchiectasis

### **Tuberculosis (TB)<sup>1916</sup>**

- Known or suspected tuberculosis and initial chest x-ray done

## Infection Follow-up Imaging

- Abscess, empyema, or pleural effusions on chest x-ray<sup>2017</sup>
- For evaluation of non-resolving pneumonia or inflammatory disease documented by **at least two** imaging studies:
  - Unimproved with 4 weeks of antibiotic treatment; **OR**
  - Unresolved at 8 weeks<sup>21, 2218, 19</sup>

## ~~Pneumothorax on Chest X-ray<sup>23</sup>~~

## ~~Vocal Cord Paralysis on Endoscopic Exam<sup>24</sup>~~

## Pneumothorax on Chest X-ray<sup>20</sup>

## Vocal Cord Paralysis on Endoscopic Exam<sup>21</sup>

- Neck and Chest CT is an approvable combo

## ~~Granulomatosis with Polyangiitis (Wegener's Granulomatosis)<sup>25</sup>~~

## Granulomatosis with Polyangiitis (Wegener's Granulomatosis)<sup>22</sup>

## Vascular Disease

- CT chest is NOT the preferred study for vascular disease, CTA should be considered. See Chest CTA guideline.
- Chest CT can be used to detect and follow-up thoracic aortic aneurysms. See Background section.

## Suspected Pulmonary Embolism (PE)<sup>2623</sup>

- Chest CT NOT approvable for PE; should be CTA

## Congenital Malformations

- Thoracic malformation on chest x-ray<sup>274</sup>
- Congenital Heart Disease with pulmonary hypertension<sup>2825</sup>

## Hemoptysis after x-ray completed<sup>29, 3026, 27</sup>

## Pre-operative/procedural evaluation

- Pre-operative evaluation for a planned surgery or procedure
- Pre-operative evaluation for Electromagnetic Navigation Bronchoscopy<sup>3128</sup> (this is a non-diagnostic CT)

## Post-operative/procedural evaluation

- Post-surgical follow-up when records document medical reason requiring additional imaging

### Chest Wall Pain (after initial evaluation with chest x-ray and/or rib films)<sup>32</sup>

- ~~History of known or suspected cancer~~

### Lung Transplant imaging<sup>29</sup>

- All potential lung transplant recipients undergo pretransplant chest CT to delineate the extent of disease, assist in surgical planning, and possible contraindications
- CT is not routinely performed for donor evaluation
- Surveillance imaging varies in frequency and modality among various transplant centers, as there is no universal protocol. (A typical protocol may include surveillance CXR in the first year, spaced out monthly and then to every 3 months until 1 year after transplant. Surveillance Chest CT is then done annually.)
- Clinical concerns for complication at any time after transplant (while initial imaging typically begins with CXR, because many of the complications following transplant do not have classic XR findings, imaging can begin with CT)

### Transplants

- Prior to solid organ transplantation
- For initial workup prior to Bone Marrow Transplant (BMT) (along with CT Abdomen and Pelvis<sup>30</sup>, CT Sinus and Brain MRI)<sup>31</sup>).

### Chest Wall

- Pain (after initial evaluation with chest x-ray and/or rib films)<sup>32</sup>
- History of known or suspected cancer
- Signs and symptoms of infection, such as: fever, elevated inflammatory markers, known infection at other sites
  - ~~Accompanying fever~~
  - ~~Elevated inflammatory markers~~
  - ~~Known infection at other sites~~
- Suspected chest wall injuries (including musculotendinous, costochondral cartilage, sternoclavicular joint, and manubriosternal joint injuries), when imaging will potentially alter management
- Malformations (such as pectus excavatum, pectus carinatum, scoliosis) in patients with cardiorespiratory symptoms for whom treatment is being considered
- Mass or lesion after inconclusive initial imaging ((MRI preferred over chest CT for chest wall mass)

### Chest CT and COVID-19 (Coronavirus)

- Acute COVID

- Imaging is indicated in a patient with COVID-19 and worsening respiratory status after chest X ray is shown to be insufficient for management or has indeterminant findings. (Imaging is NOT indicated in patients ~~suspected of having coronavirus disease (COVID-19)~~ and with Covid who have mild clinical features unless they are at risk for disease progression)
- ~~Imaging is indicated in a patient with COVID-19 and worsening respiratory status~~
- ~~In a resource-constrained environment, imaging is indicated for medical triage of patients suspected of having COVID-19 who present with moderate-to-severe clinical features and a high pretest probability of disease~~
- Long (Chronic) COVID (See Overview)
  - Prior history of Covid with hypoxia or impaired lung function of follow-up<sup>33</sup>
    - Restricted diffusion on Pulmonary Function Test (would need a HRCT – High Resolution CT)
    - Low oxygen saturation and a Chest x-ray was done
  - Known fibrosis with continued symptoms

### Pulmonary Hypertension<sup>34</sup>

Pulmonary artery diameter/ascending aortic diameter  $\geq 1$  measured on Chest CT can be used as a reliable method for early diagnosis of PH

### Miscellaneous

- When clinical or laboratory findings remain unexplained after negative CXR and initial work up appropriate to the findings fail to determine their etiology, yet chest pathology remains as possible cause such as
  - Weight loss when initial workup and abdomen/pelvis CT/MR fail to identify the cause for weight loss can Chest CT be approved. If CXR suggests a malignancy and/or source of weight loss, then Chest CT would be approvable on the basis of abnormal CXR
  - For confirmed gestational trophoblastic disease when HCG fails to decline appropriately following surgery<sup>35</sup>
- Multiple Endocrine Neoplasia type 1 (MEN1) every 1-3 years (chest CT or MRI also approvable for this syndrome at same interval)<sup>36</sup>

### Other Indications

Further evaluation of indeterminate findings on prior imaging (unless follow up is otherwise specified within the guideline):

- For initial evaluation of an inconclusive finding on a prior imaging report that requires further clarification
- One follow-up exam of a prior indeterminate MR/CT finding to ensure no suspicious interval change has occurred. (No further surveillance unless specified as highly suspicious or change was found on last follow-up exam.)

## Combination of studies with Chest CT

- **Abdomen CT/Pelvis CT/Chest CT/Neck MRI/Neck CT with MUGA** – known tumor/cancer for initial staging or evaluation before starting chemotherapy or radiation treatment
  - **Neck and Chest CT** - Neck and Chest CT is an approvable combo with vocal cord paralysis and concern for recurrent laryngeal nerve lesion
- 

## BACKGROUND

Computed tomography (CT) scans provide greater clarity than regular x-rays and are used to further examine abnormalities found on chest x-rays. They may be used for detection and evaluation of various disease and conditions in the chest, e.g., tumor, inflammatory disease, vascular disease, congenital abnormalities, trauma, and symptoms such as hemoptysis.

## OVERVIEW

**LDCT for Lung Cancer Screening** - Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.

## CT and Aneurysm

- Initial evaluation of aneurysm<sup>34-3637-39</sup>
  - Echocardiogram shows aneurysm
  - Echocardiogram inconclusive of proximal aorta and first-degree relative with thoracic aneurysm
  - Chest x-ray shows possible aneurysm
- Follow-up after established Thoracic Aneurysm (above these sizes surgery is usually recommended)<sup>34-3637-39</sup>
  - Aortic Root or Ascending Aorta
    - 3.5 to 4.5 - Annual
    - 4.5 to 5.4 - Every 6 months
  - Genetically mediated (Marfan's syndrome, Aortic Root or Ascending Aorta)<sup>40</sup>
    - 3.5 to 4.0 - Annual
    - 4.0 to 5.0 - Every 6 months
  - Descending Aorta
    - 4.0 to 5.0 - Annual
    - 5.0 to 6.0 - Every 6 months

**CT and Interstitial Lung Disease<sup>44</sup>CT and Interstitial Lung Disease<sup>40</sup>** – Radiography of the chest is usually appropriate for the initial imaging of patients who undergo screening and surveillance for lung disease when occupational exposure is present.

**Costochondritis**<sup>37,41</sup> – If physical exam findings are suggestive of costochondritis but the pain is persistent despite conservative care, it should be kept in mind that costochondritis can be recurrent and persistent. It is associated with fibromyalgia. Chest CT should be considered if the findings are not consistent with typical costochondritis, such as fever or elevated inflammatory markers, suggestive of infection or a suspicion of cancer based on history or current findings.

**CT for Management of Hemoptysis**<sup>29,30,26, 27</sup> – High-resolution CT (HRCT) is useful for estimating the severity of hemoptysis, localizing the bleeding site and determining the cause of the bleeding. Its results can be related to the severity of bleeding. The volume of expectorated blood and the amount of blood that may be retained within the lungs without being coughed up are important. HRCT is a way to evaluate the amount of bleeding and its severity. It may also help in the localization of bleeding sites and help in detecting the cause of bleeding.

**CT and Solitary Pulmonary Nodules** – Solitary Pulmonary nodules are abnormalities that are solid, semisolid and non-solid; another term to describe a nodule is focal opacity. CT makes it possible to find smaller nodules and contrast-enhanced CT is used to differentiate benign from malignant pulmonary modules. When a nodule is increasing in size or has spiculated margins or mixed solid and ground-glass attenuation, malignancy should be expected. Patients who have pulmonary nodules and who are immunocompromised may be subject to inflammatory processes.

**CT and Empyema** – Contrast-enhanced CT used in the evaluation of the chest wall may detect pleural effusion and differentiate a peripheral pulmonary abscess from a thoracic empyema. CT may also detect pleural space infections and help in the diagnosis and staging of thoracic empyema.

**CT and Rib fractures**<sup>38,42</sup> – Chest CT may be useful for characterizing a pathologic fracture, and some features may be helpful in differentiating a primary malignant tumor of bone from metastasis. CT may also be helpful to search for a primary malignancy in patients with a suspected pathologic fracture; however, there is no strong indication that CT serves a significant use as the initial imaging modality to detect pathologic rib fractures.

**CT and Occupational Lung Disease**<sup>14</sup> – ~~The chest radiograph and CT are complementary in the initial workup of suspected occupational lung disease.~~<sup>40</sup> – The chest radiograph and CT are complementary in the initial workup of suspected occupational lung disease. When patients with occupational exposures present with respiratory symptoms, chest radiography serves as the primary function of excluding alternative diagnoses, such as infectious pneumonia or pulmonary edema, with HRCT findings offering the best characterization of lung disease.

**CT and Tuberculosis** – “The chest radiograph is usually the first study performed in patients suspected of having TB. Although frontal and lateral radiographs are often performed in this setting, it has been shown that the lateral radiograph does not improve the detection of findings related to TB. In those with signs or symptoms of disease, the radiographic pattern of



upper-lobe or superior-segment lower-lobe fibrocavitary disease in the appropriate clinical setting is sufficient to warrant respiratory isolation and sputum culture for definitive diagnosis. Using radiographs in combination with clinical evaluation results in a high sensitivity for the diagnosis but a relatively low specificity for both latent and active TB. In addition, radiographs may reveal ancillary findings of TB such as pleural effusion or spondylitis. For immunocompromised hosts, particularly those with a low CD4 count, computed tomography (CT) should be considered.”<sup>39,43</sup> CT may be of value in the severely immunocompromised patient with a normal or near-normal radiograph by revealing abnormal lymph nodes or subtle parenchymal disease. Finally, CT may also have a role in identifying patients with latent TB who will be at risk for reactivation disease.

**CT and Superior Vena Cava (SVC) Syndrome** – SVC is associated with cancer, e.g., lung, breast and mediastinal neoplasms. These malignant diseases cause invasion of the venous intima or an extrinsic mass effect. Adenocarcinoma of the lung is the most common cause of SVC. SVC is a clinical diagnosis with typical symptoms of shortness of breath along with facial and upper extremity edema. Computed tomography (CT), often the most readily available technology, may be used as confirmation and may provide information including possible causes.

**CT and Family History of Lung Cancer**<sup>40,44</sup> – Family history is equally important. Individuals with a family history of lung cancer among first-degree relatives have been consistently shown to have a two-fold higher risk of developing lung cancer themselves. Those with multiple affected family members diagnosed at younger age appear to be at greater risk.

**CT and COVID-19 – Chest CT is not recommended as a screening test for COVID-19 or as a first-line test to diagnose COVID-19 due to its poor sensitivity and specificity.<sup>45, 46</sup> It is only needed when expected to guide clinical management, such as for patients with moderate to severe disease who show lack of respiratory improvement, unexplained deterioration, or worsening gas exchange. In patients with associated co-morbidities (age >65 yr., diabetes, hypertension, obesity, cardiovascular disease, chronic respiratory disease, immune compromise, etc.), CT may be useful in these patients when they have mild symptoms and a normal or indeterminate CXR but have an oxygen saturation <93% at rest on room air or who de-saturate on a 6-minute walk test. In an acute setting, CT can assist in the determining the need for hospitalization. In subacute and chronic settings, it can help predict which patients are likely to have residual pulmonary involvement. CT can also help rule out lung fibrosis in patients recovered from COVID-19 infection that present with hypoxia/impaired lung function on follow up.<sup>47, 48</sup>**

### **Fever of Unknown Origin**

**Initial work up prior to CT would include a comprehensive history, repeated physical exam, complete blood count with differential, three sets of blood cultures, chest x-ray, complete metabolic panel, urinalysis, ESR, ANA, RA, CMV IgM antibodies, virus detection in blood, heterophile antibody test, tuberculin test, and HIV antibody test.<sup>61</sup> Lastly, with a negative**

CXR, only when initial workup and abdomen/pelvis CT/MR fail to identify the cause for fever can Chest CT be approved. If CXR suggests a malignancy and/or source of fever, then Chest CT would be approved.

Suspected paraneoplastic syndromes with no established cancer diagnosis: laboratory evaluation and imaging

The laboratory evaluation for paraneoplastic syndrome is complex. If the appropriate lab test results are suspicious for malignancy, imaging is indicated.

For SIADH (hyponatremia + increased urine osmolality), there is a high association with small cell lung cancer, therefore imaging typically starts with chest CT. If other symptoms suggest a different diagnosis other than small cell lung cancer, different imaging studies may be reasonable.

For hypercalcemia (high serum calcium, low-normal PTH, high PTHrP) it is reasonable to start with bone imaging followed by a more directed evaluation such as mammogram, chest, abdomen and pelvis imaging as appropriate.

For Cushing syndrome (hypokalemia, normal-high midnight serum ACTH NOT suppressed with dexamethasone) abdominal and chest imaging is reasonable. If dexamethasone suppression test DOES suppress ACTH, pituitary MRI is reasonable.

For hypoglycemia, labs drawn during a period of hypoglycemia (glucose < 55, typically a 72 hour fast) (insulin level, C-peptide and IGF-2:IGF-1 ratio) should be done to evaluate for an insulinoma. An elevated insulin level, elevated C-peptide and/or normal IGF-2:IGF-1 ratio warrant CT or MRI abdomen to look for insulinoma. A low insulin, low C-peptide and/or elevated IGF-2:IGF-1 ratio warrant chest and abdominal imaging.

When a paraneoplastic neurologic syndrome is suspected, nuclear and cytoplasmic antibody panels are often ordered to further identify specific tumor types. Results are needed prior to imaging. Because these tests are highly specific, if an antibody highly associated with a specific cancer is positive, then further imaging for that cancer is reasonable. For example, anti-Hu has a high association with SCLC and chest CT would be reasonable. Anti-MA2 has a high association with testicular cancer and testicular ultrasound would be a reasonable next step.

Weight loss definitions and initial evaluation – Unintentional weight loss is considered clinically significant if the amount of weight lost over 12 months is  $\geq 5\%$ . Older age and higher percentage of weight loss correlate with higher likelihood of malignancy. A targeted evaluation is recommended when there are signs or symptoms suggestive of a specific source. For example, when there is clinically significant weight loss with abdominal pain that prompts an evaluation for an abdominal source of the weight loss; CXR and labs such as TSH would not be needed prior to abdominal imaging. Conversely a smoker with a cough and

weight loss would not start with abdominal imaging, a chest x-ray (CXR) would be the first test to start with. When there is no suspected diagnosis, initial evaluation includes CXR, age-appropriate cancer screening (such as colonoscopy and mammography) and labs (including CBC, CMP, HbA1C, TSH, stool hemoccult, ESR/CRP, HIV, Hepatitis C). If this initial evaluation fails to identify a cause of weight loss, then the patient is monitored and if progressive weight loss is seen on subsequent visits/weights, then CT Abdomen/Pelvis is reasonable (MRI if there is a contraindication to CT such as contrast allergy or impaired renal function). Lastly, with a negative CXR, only when initial workup and abdomen/pelvis CT/MR fail to identify the cause for weight loss can Chest CT be approved. If CXR suggests a malignancy and/or source of weight loss, then Chest CT would be approved.

~~**CT and COVID-19**—Chest CT is not recommended by the American College of Radiology either as a screening test for COVID-19 or as a first-line test to diagnose COVID-19.<sup>41</sup> The chest imaging pattern is nonspecific to COVID-19 and may be dependent on radiographic interpretation.<sup>42-48</sup> The CDC differentiates long COVID—also known as long-haul COVID, post-acute COVID-19, long-term effects of COVID, or chronic COVID—as post-COVID conditions that “are a wide range of new, returning, or ongoing health problems people can experience four or more weeks after first being infected with the virus that causes COVID-19. Even people who did not have COVID-19 symptoms in the days or weeks after they were infected can have post-COVID conditions. These conditions can present as different types and combinations of health problems for different lengths of time.”<sup>49</sup>~~

## REFERENCES

1. Final Recommendation Statement Lung Cancer: Screening U.S. Preventive Services Task Force (USPSTF). Updated March 9, 2021. Accessed November 20, 2022. <https://uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening>
2. Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. *J Natl Compr Canc Netw*. Feb 2012;10(2):240-65. doi:10.6004/jnccn.2012.0022
3. McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. Performance of ACR Lung-RADS in a clinical CT lung screening program. *J Am Coll Radiol*. Mar 2015;12(3):273-6. doi:10.1016/j.jacr.2014.08.004
4. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. *Ann Intern Med*. Apr 7 2015;162(7):485-91. doi:10.7326/m14-2086
5. Lung-RADS® Version 1.1. American College of Radiology (ACR). Updated 2019. Accessed November 20, 2022. <https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf>
6. Bueno J, Landeras L, Chung JH. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios. *Radiographics*. Sep-Oct 2018;38(5):1337-1350. doi:10.1148/rg.2018180017
7. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology*. 2017;284(1):228-243. doi:10.1148/radiol.2017161659
8. Carter BW, Lichtenberger JP, 3rd, Benveniste MK, et al. Revisions to the TNM Staging of Lung Cancer: Rationale, Significance, and Clinical Application. *Radiographics*. Mar-Apr 2018;38(2):374-391. doi:10.1148/rg.2018170081
9. Hong SJ, Kim TJ, Nam KB, et al. New TNM staging system for esophageal cancer: what chest radiologists need to know. *Radiographics*. Oct 2014;34(6):1722-40. doi:10.1148/rg.346130079
10. Lee SC, Jain PA, Jethwa SC, Tripathy D, Yamashita MW. Radiologist's role in breast cancer staging: providing key information for clinicians. *Radiographics*. Mar-Apr 2014;34(2):330-42. doi:10.1148/rg.342135071
11. Greco FA, Oien K, Erlander M, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. *Ann Oncol*. Feb 2012;23(2):298-304. doi:10.1093/annonc/mdr306
12. Mullan CP, Madan R, Trotman-Dickenson B, Qian X, Jacobson FL, Hunsaker A. Radiology of chest wall masses. *AJR Am J Roentgenol*. Sep 2011;197(3):W460-70. doi:10.2214/ajr.10.7259
13. Kumar R. Myasthenia gravis and thymic neoplasms: A brief review. *World J Clin Cases*. Dec 16 2015;3(12):980-3. doi:10.12998/wjcc.v3.i12.980
14. ACR-STR Practice Parameter for the Performance of High-Resolution Computed Tomography (HRCT) of the Lungs in Adults. American College of Radiology (ACR). Updated 2020. Accessed November 20, 2022. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/HRCT-Lungs.pdf>

15. Turner RD, Bothamley GH. Chronic cough and a normal chest X-ray - a simple systematic approach to exclude common causes before referral to secondary care: a retrospective cohort study. *NPJ Prim Care Respir Med*. Mar 3 2016;26:15081. doi:10.1038/npjpcrm.2015.81
16. Ko Y, Lee HY, Park YB, et al. Correlation of microbiological yield with radiographic activity on chest computed tomography in cases of suspected pulmonary tuberculosis. *PLoS One*. 2018;13(8):e0201748. doi:10.1371/journal.pone.0201748
17. Dean NC, Griffith PP, Sorensen JS, McCauley L, Jones BE, Lee YC. Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With Pneumonia. *Chest*. Jun 2016;149(6):1509-15. doi:10.1016/j.chest.2015.12.027
18. Bryl B, Barlow E, Davies H. P182 Follow up chest X-rays (CXR) after community acquired pneumonia (CAP): are they done and are they useful? *Thorax*. 2018;73(Suppl 4):A199-A200. doi:10.1136/thorax-2018-212555.339
19. Little BP, Gilman MD, Humphrey KL, et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. *AJR Am J Roentgenol*. Jan 2014;202(1):54-9. doi:10.2214/ajr.13.10888
20. Melamed KH, Abtin F, Barjaktarevic I, Cooper CB. Diagnostic Value of Quantitative Chest CT Scan in a Case of Spontaneous Pneumothorax. *Chest*. Nov 2017;152(5):e109-e114. doi:10.1016/j.chest.2017.07.013
21. Paquette CM, Manos DC, Psooy BJ. Unilateral vocal cord paralysis: a review of CT findings, mediastinal causes, and the course of the recurrent laryngeal nerves. *Radiographics*. May-Jun 2012;32(3):721-40. doi:10.1148/rg.323115129
22. Li J, Li C, Li J. Thoracic manifestation of Wegener's granulomatosis: Computed tomography findings and analysis of misdiagnosis. *Exp Ther Med*. Jul 2018;16(1):413-419. doi:10.3892/etm.2018.6154
23. Kirsch J, Brown RKJ, Henry TS, et al. ACR Appropriateness Criteria(®) Acute Chest Pain-Suspected Pulmonary Embolism. *J Am Coll Radiol*. May 2017;14(5s):S2-s12. doi:10.1016/j.jacr.2017.02.027
24. Ferreira Tda A, Chagas IS, Ramos RT, Souza EL. Congenital thoracic malformations in pediatric patients: two decades of experience. *J Bras Pneumol*. Mar-Apr 2015;41(2):196-9. doi:10.1590/s1806-37132015000004374
25. Pascall E, Tulloh RM. Pulmonary hypertension in congenital heart disease. *Future Cardiol*. Jul 2018;14(4):343-353. doi:10.2217/fca-2017-0065
26. American College of Radiology. ACR Appropriateness Criteria® Hemoptysis. American College of Radiology (ACR). Updated 2019. Accessed November 20, 2022. <https://acsearch.acr.org/docs/69449/Narrative/>
27. Ketai LH, Mohammed TL, Kirsch J, et al. ACR appropriateness criteria® hemoptysis. *J Thorac Imaging*. May 2014;29(3):W19-22. doi:10.1097/rti.0000000000000084
28. Khan KA, Nardelli P, Jaeger A, O'Shea C, Cantillon-Murphy P, Kennedy MP. Navigational Bronchoscopy for Early Lung Cancer: A Road to Therapy. *Adv Ther*. Apr 2016;33(4):580-96. doi:10.1007/s12325-016-0319-4
29. Kim SJ, Azour L, Hutchinson BD, et al. Imaging Course of Lung Transplantation: From Patient Selection to Postoperative Complications. *RadioGraphics*. 2021;41(4):1043-1063. doi:10.1148/rg.2021200173



30. Gerull S, Medinger M, Heim D, Passweg J, Stern M. Evaluation of the Pretransplantation Workup before Allogeneic Transplantation. *Biology of Blood and Marrow Transplantation*. 2014/11/01/ 2014;20(11):1852-1856. doi:<https://doi.org/10.1016/j.bbmt.2014.06.029>
31. Kaste SC, Kaufman RA, Sunkara A, et al. Routine pre- and post-hematopoietic stem cell transplant computed tomography of the abdomen for detecting invasive fungal infection has limited value. *Biol Blood Marrow Transplant*. Jun 2015;21(6):1132-5. doi:10.1016/j.bbmt.2015.02.023
32. Winzenberg T, Jones G, Callisaya M. Musculoskeletal chest wall pain. *Aust Fam Physician*. Aug 2015;44(8):540-4.
33. Rubin GD, Ryerson CJ, Haramati LB, et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*. Jul 2020;296(1):172-180. doi:10.1148/radiol.2020201365
34. Chen R, Liao H, Deng Z, et al. Efficacy of computed tomography in diagnosing pulmonary hypertension: A systematic review and meta-analysis. *Front Cardiovasc Med*. 2022;9:966257. doi:10.3389/fcvm.2022.966257
35. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gestational Trophoblastic Neoplasia. National Comprehensive Cancer Network®. Updated December 20, 2022. Accessed March 13, 2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/gtn.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gtn.pdf)
36. Network® NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. National Comprehensive Cancer Network®. Updated February 13, 2023. Accessed March 13, 2023. [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_bop.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf)
37. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. Nov 1 2014;35(41):2873-926. doi:10.1093/eurheartj/ehu281
38. Hannuksela M, Stattin EL, Johansson B, Carlberg B. Screening for Familial Thoracic Aortic Aneurysms with Aortic Imaging Does Not Detect All Potential Carriers of the Disease. *Aorta (Stamford)*. Feb 2015;3(1):1-8. doi:10.12945/j.aorta.2015.14-052
39. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *Circulation*. Apr 6 2010;121(13):e266-369. doi:10.1161/CIR.0b013e3181d4739e
40. American College of Radiology. ACR Appropriateness Criteria® Occupational Lung Diseases. American College of Radiology. Updated 2019. Accessed November 20, 2022. <https://acsearch.acr.org/docs/3091680/Narrative/>

41. Proulx AM, Zryd TW. Costochondritis: diagnosis and treatment. *Am Fam Physician*. Sep 15 2009;80(6):617-20.
42. American College of Radiology. ACR Appropriateness Criteria® Rib Fractures. American College of Radiology. Updated 2018. Accessed November 20, 2022. <https://acsearch.acr.org/docs/69450/Narrative/>
43. American College of Radiology. ACR Appropriateness Criteria® Imaging of Possible Tuberculosis. American College of Radiology (ACR). Updated 2016. Accessed November 20, 2022. <https://acsearch.acr.org/docs/3099187/Narrative/>
44. Loverdos K, Fotiadis A, Kontogianni C, Iliopoulou M, Gaga M. Lung nodules: A comprehensive review on current approach and management. *Ann Thorac Med*. Oct-Dec 2019;14(4):226-238. doi:10.4103/atm.ATM\_110\_19
45. Prevention CfDCA. Clinical Care Considerations: Clinical considerations for care of children and adults with confirmed COVID-19. Centers for Disease Control and Prevention. Updated January 27, 2023. Accessed February 22, 2023. [https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-index.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fclinical-guidance-management-patients.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fclinical-guidance-management-patients.html)
46. Long COVID or Post-COVID Conditions. Centers for Disease Control & Prevention (CDC). Updated December 16, 2022. Accessed January 19, 2023. <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>
47. Garg M, Prabhakar N, Bhalla AS, et al. Computed tomography chest in COVID-19: When & why? *Indian J Med Res*. Jan & Feb 2021;153(1 & 2):86-92. doi:10.4103/ijmr.IJMR\_3669\_20
48. Machnicki S, Patel D, Singh A, et al. The Usefulness of Chest CT Imaging in Patients With Suspected or Diagnosed COVID-19: A Review of Literature. *Chest*. Aug 2021;160(2):652-670. doi:10.1016/j.chest.2021.04.004

## POLICY HISTORY

Date	Summary
<u>May 2023</u>	<ul style="list-style-type: none"> <li>• <u>Added FUO, weight loss and paraneoplastic information to background</u></li> <li>• <u>Updated Covid information in the background</u></li> <li>• <u>Clarified details on nodules seen on other imaging such as non-chest CT or non CXR</u></li> <li>• <u>Added transplant imaging</u></li> <li>• <u>Clarified non cigarette smoking for LDCT</u></li> <li>• <u>General Information moved to beginning of guideline with added statement on clinical indications not addressed in this guideline</u></li> <li>• <u>Added statement regarding further evaluation of indeterminate findings on prior imaging</u></li> </ul>
March 2022	<ul style="list-style-type: none"> <li>• Clarified that no time delay required between chest x-ray and subsequent Chest CT for indeterminate incidental pulmonary nodules on chest x-ray (not typical of granulomatous disease)</li> <li>• Moved “Pre-operative evaluation for Electromagnetic Navigation Bronchoscopy” from Post-operative/procedural evaluation to Pre-operative/procedural evaluation</li> <li>• Added known fibrosis with continued symptoms to Long (Chronic) COVID</li> </ul>
<del>April 2021</del>	<ul style="list-style-type: none"> <li>• <del>Added details for the following: incidental lung nodules as per the Fleischner Society; when not to use the Fleischner criteria; ordering of a Chest CT in the setting of coronavirus infection</del></li> <li>• <del>Clarified when to use Lung Rads versus Fleischner criteria</del></li> <li>• <del>Clarified pre-operative evaluation for a planned surgery or procedure</del></li> <li>• <del>Added indications on what to image in setting of Covid-19</del></li> </ul>
<del>March 10, 2021</del>	<ul style="list-style-type: none"> <li>• <del>Eliminated groupings (group 1 and group 2) for lung cancer screening and changed age of 55-80 years to 50-80 years; removed 30 pack-year history of cigarette smoking (USPSTF 2021)</del></li> </ul>
<del>November 9, 2020</del>	<ul style="list-style-type: none"> <li>• <del>Replaced CPT code G0297 with 71271</del></li> </ul>
<del>May 2020</del>	<ul style="list-style-type: none"> <li>• <del>For Annual Lung Cancer Screening:</del> <ul style="list-style-type: none"> <li>○ <del>Changed upper age limit from 77 to 80 yrs old</del></li> <li>○ <del>Added:</del> <ul style="list-style-type: none"> <li>• <del>Age ≥ 50 years old; AND</del></li> <li>• <del>≥ 20 pack year history of smoking; AND</del></li> <li>• <del>Additional risk factors (other than second hand smoke)* (see pg 2)</del></li> </ul> </li> </ul> </li> </ul> <p><del>*Additional risk factors include: Survivors of lung cancer, lymphoma, cancers of the head and neck and bladder (smoking related cancers);</del></p>

~~first degree family members with a history of lung cancer, history of COPD or pulmonary fibrosis, radon exposure, retinoblastoma, Li Fraumeni syndrome, occupational exposure to arsenic, chromium, asbestos, nickel, cadmium, beryllium, silica, diesel fumes, coal smoke and soot~~

- ~~• Expanded lung nodules section to include:
 
  - ~~○ Incidental pulmonary nodules detected on CT (use Fleischner Table)~~
    - ~~• Age  $\geq 35$  years old — use Fleischner table~~
    - ~~• Excludes lung cancer screening, patients with history of primary cancer, or immunosuppression (see specific section in current guideline)~~
  - ~~○ Incidental pulmonary nodules on non-chest CT:
 
    - ~~• Nodules  $> 8$ mm or those with very suspicious features need further Chest CT as early as possible~~
    - ~~• Nodules  $\leq 8$ mm should follow the Fleischner table~~~~~~
- ~~• For Known Cancer, added: For follow-up intervals for malignancies~~
- ~~• For Lung or Chest Wall Mass:
 
  - ~~○ Added statement: Preference should be given to MRI over chest CT for chest wall mass~~
    - ~~• Removed descriptive variables for 'Mass with increased risk for malignancy' including: Fixation to adjacent tissues; Firm consistency; Size  $> 1.5$  cm; Ulceration of overlying skin~~~~
- ~~• Expanded Interstitial Lung Disease section to include:
 
  - ~~○ Suspected or known based on restrictive pattern pulmonary function test or signs or symptoms after initial chest x-ray~~
  - ~~○ Signs or symptoms unresponsive to treatment such as:
 
    - ~~▪ Shortness of breath~~
    - ~~▪ Persistent dyspnea~~
    - ~~▪ Persistent cough~~~~
  - ~~○ Patients with known collagen vascular disease~~
  - ~~○ Guidance in selection of the most appropriate site for biopsy of diffuse lung disease~~~~
- ~~• Infection f/u imaging: added inflammatory disease~~
- ~~• Vocal Cord Paralysis on Endoscopic Exam: added 'Neck and Chest CT is an approvable combo'~~
- ~~• Removed Vascular Disease section and added the following:
 
  - ~~○ CT chest is not preferred study for vascular disease, CTA should be considered. See Chest CTA guideline.~~
  - ~~○ Chest CT can be used to detect and follow-up thoracic aortic aneurysms.~~~~
- ~~• Added indication: Chest Wall Pain~~

	<ul style="list-style-type: none"> <li>○ <del>Chest Wall Pain (after initial evaluation with chest x-ray and/or rib films)</del></li> <li>▪ <del>History of known or suspected cancer</del></li> <li>▪ <del>Signs and symptoms of infection, such as:</del> <ul style="list-style-type: none"> <li>● <del>Accompanying fever</del></li> <li>● <del>Elevated inflammatory markers</del></li> <li>● <del>Known infection at other sites</del></li> </ul> </li> <li>● <del>Added Neck and Chest CT combo study</del></li> </ul>
May 2019	<ul style="list-style-type: none"> <li>● <del>Added chart for f/u interval at which LDCT can be approved</del></li> <li>● <del>Removed pulmonary embolism indication</del></li> <li>● <del>Added statement about CPT codes</del></li> <li>● <del>Separate diagnostic criteria for Thoracic aneurysm</del></li> <li>● <del>Separated individual diagnoses.</del></li> <li>● <del>Expanded criteria for chronic cough.</del></li> <li>● <del>Updated references.</del></li> </ul>

## REFERENCES

1. Final Recommendation Statement Lung Cancer: Screening U.S. Preventive Services Task Force (USPSTF). Updated March 9, 2021. Accessed November 16, 2021. <https://uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening>
2. Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. *J Natl Compr Canc Netw*. Feb 2012;10(2):240-65. doi:10.6004/jncn.2012.0022
3. McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. Performance of ACR Lung RADS in a clinical CT lung screening program. *J Am Coll Radiol*. Mar 2015;12(3):273-6. doi:10.1016/j.jacr.2014.08.004
4. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung RADS in the National Lung Screening Trial: a retrospective assessment. *Ann Intern Med*. Apr 7 2015;162(7):485-91. doi:10.7326/m14-2086
5. Lung RADS® Version 1.1. American College of Radiology (ACR). Updated 2019. Accessed November 16, 2021. <https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf>
6. Bueno J, Landeras L, Chung JH. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios. *Radiographics*. Sep-Oct 2018;38(5):1337-1350. doi:10.1148/rg.2018180017
7. Carter BW, Lichtenberger JP, 3rd, Benveniste MK, et al. Revisions to the TNM Staging of Lung Cancer: Rationale, Significance, and Clinical Application. *Radiographics*. Mar-Apr 2018;38(2):374-391. doi:10.1148/rg.2018170081
8. Hong SJ, Kim TJ, Nam KB, et al. New TNM staging system for esophageal cancer: what chest radiologists need to know. *Radiographics*. Oct 2014;34(6):1722-40. doi:10.1148/rg.346130079
9. Lee SC, Jain PA, Jethwa SC, Tripathy D, Yamashita MW. Radiologist's role in breast cancer staging: providing key information for clinicians. *Radiographics*. Mar-Apr 2014;34(2):330-42. doi:10.1148/rg.342135071
10. NCCN Imaging Appropriate Use Criteria™. National Comprehensive Cancer Network (NCCN). Updated 2021. Accessed November 4, 2021. <https://www.nccn.org/professionals/imaging/default.aspx>
11. Greco FA, Oien K, Erlander M, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. *Ann Oncol*. Feb 2012;23(2):298-304. doi:10.1093/annonc/mdr306
12. Mullan CP, Madan R, Trotman-Dickenson B, Qian X, Jacobson FL, Hunsaker A. Radiology of chest wall masses. *AJR Am J Roentgenol*. Sep 2011;197(3):W460-70. doi:10.2214/ajr.10.7259
13. Kumar R. Myasthenia gravis and thymic neoplasms: A brief review. *World J Clin Cases*. Dec 16 2015;3(12):980-3. doi:10.12998/wjcc.v3.i12.980
14. American College of Radiology. ACR Appropriateness Criteria® Occupational Lung Diseases. American College of Radiology. Updated 2019. Accessed November 16, 2021. <https://acsearch.acr.org/docs/3091680/Narrative/>
15. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. *Chest*. Mar 2013;143(3):814-824. doi:10.1378/chest.12-0741



16. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. *Eur Respir J*. Apr 2009;33(4):882-96. doi:10.1183/09031936.00152607
17. ACR STR Practice Parameter for the Performance of High-Resolution Computed Tomography (HRCT) of the Lungs in Adults. American College of Radiology (ACR). Updated 2020. Accessed November 16, 2021. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/HRCT-Lungs.pdf>
18. Turner RD, Bothamley GH. Chronic cough and a normal chest X-ray—a simple systematic approach to exclude common causes before referral to secondary care: a retrospective cohort study. *NPJ Prim Care Respir Med*. Mar 3 2016;26:15081. doi:10.1038/npjperm.2015.81
19. Ko Y, Lee HY, Park YB, et al. Correlation of microbiological yield with radiographic activity on chest computed tomography in cases of suspected pulmonary tuberculosis. *PLoS One*. 2018;13(8):e0201748. doi:10.1371/journal.pone.0201748
20. Dean NC, Griffith PP, Sorensen JS, McCauley L, Jones BE, Lee YC. Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With Pneumonia. *Chest*. Jun 2016;149(6):1509-15. doi:10.1016/j.chest.2015.12.027
21. Bryl B, Barlow E, Davies H. P182 Follow up chest X-rays (CXR) after community acquired pneumonia (CAP): are they done and are they useful? *Thorax*. 2018;73(Suppl 4):A199-A200. doi:10.1136/thorax-2018-212555.339
22. Little BP, Gilman MD, Humphrey KL, et al. Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography. *AJR Am J Roentgenol*. Jan 2014;202(1):54-9. doi:10.2214/ajr.13.10888
23. Melamed KH, Abtin F, Barjaktarevic I, Cooper CB. Diagnostic Value of Quantitative Chest CT Scan in a Case of Spontaneous Pneumothorax. *Chest*. Nov 2017;152(5):e109-e114. doi:10.1016/j.chest.2017.07.013
24. Paquette CM, Manos DC, Psooy BJ. Unilateral vocal cord paralysis: a review of CT findings, mediastinal causes, and the course of the recurrent laryngeal nerves. *Radiographics*. May Jun 2012;32(3):721-40. doi:10.1148/rg.323115129
25. Li J, Li C, Li J. Thoracic manifestation of Wegener's granulomatosis: Computed tomography findings and analysis of misdiagnosis. *Exp Ther Med*. Jul 2018;16(1):413-419. doi:10.3892/etm.2018.6154
26. Kirsch J, Brown RKJ, Henry TS, et al. ACR Appropriateness Criteria® Acute Chest Pain-Suspected Pulmonary Embolism. *J Am Coll Radiol*. May 2017;14(5s):S2-S12. doi:10.1016/j.jacr.2017.02.027
27. Ferreira Tda A, Chagas IS, Ramos RT, Souza EL. Congenital thoracic malformations in pediatric patients: two decades of experience. *J Bras Pneumol*. Mar-Apr 2015;41(2):196-9. doi:10.1590/s1806-37132015000004374
28. Pascall E, Tulloh RM. Pulmonary hypertension in congenital heart disease. *Future Cardiol*. Jul 2018;14(4):343-353. doi:10.2217/fca-2017-0065
29. American College of Radiology. ACR Appropriateness Criteria® Hemoptysis. American College of Radiology (ACR). Updated 2019. Accessed November 16, 2021. <https://acsearch.acr.org/docs/69449/Narrative/>

30. Ketai LH, Mohammed TL, Kirsch J, et al. ACR appropriateness criteria® hemoptysis. *J Thorac Imaging*. May 2014;29(3):W19-22. doi:10.1097/rti.0000000000000084
31. Khan KA, Nardelli P, Jaeger A, O'Shea C, Cantillon-Murphy P, Kennedy MP. Navigational Bronchoscopy for Early Lung Cancer: A Road to Therapy. *Adv Ther*. Apr 2016;33(4):580-96. doi:10.1007/s12325-016-0319-4
32. Winzenberg T, Jones G, Callisaya M. Musculoskeletal chest wall pain. *Aust Fam Physician*. Aug 2015;44(8):540-4.
33. Rubin GD, Ryerson CJ, Haramati LB, et al. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*. Jul 2020;296(1):172-180. doi:10.1148/radiol.2020201365
34. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. Nov 1 2014;35(41):2873-926. doi:10.1093/eurheartj/ehu281
35. Hannuksela M, Stattin EL, Johansson B, Carlberg B. Screening for Familial Thoracic Aortic Aneurysms with Aortic Imaging Does Not Detect All Potential Carriers of the Disease. *Aorta (Stamford)*. Feb 2015;3(1):1-8. doi:10.12945/j.aorta.2015.14-052
36. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *Circulation*. Apr 6 2010;121(13):e266-369. doi:10.1161/CIR.0b013e3181d4739e
37. Proulx AM, Zryd TW. Costochondritis: diagnosis and treatment. *Am Fam Physician*. Sep 15 2009;80(6):617-20.
38. American College of Radiology. ACR Appropriateness Criteria® Rib Fractures. American College of Radiology. Updated 2018. Accessed November 19, 2021. <https://acsearch.acr.org/docs/69450/Narrative/>
39. American College of Radiology. ACR Appropriateness Criteria® Imaging of Possible Tuberculosis. American College of Radiology (ACR). Updated 2016. Accessed November 19, 2021. <https://acsearch.acr.org/docs/3099187/Narrative/>
40. Loverdos K, Fotiadis A, Kontogianni C, Iliopoulou M, Gaga M. Lung nodules: A comprehensive review on current approach and management. *Ann Thorac Med*. Oct-Dec 2019;14(4):226-238. doi:10.4103/atm.ATM\_110\_19
41. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. American College of Radiology (ACR). Updated March 22, 2020. Accessed February 21, 2022. <https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection>

42. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. *AJR Am J Roentgenol*. 2020/05/01 2020;214(5):1072-1077. doi:10.2214/AJR.20.22976
43. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). *Radiology*. Jun 2020;295(3):715-721. doi:10.1148/radiol.202000370
44. Bai HX, Hsieh B, Xiong Z, et al. Performance of Radiologists in Differentiating COVID-19 from Non-COVID-19 Viral Pneumonia at Chest CT. *Radiology*. Aug 2020;296(2):E46-e54. doi:10.1148/radiol.202000823
45. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing. *Radiology*. Aug 2020;296(2):E41-e45. doi:10.1148/radiol.202000343
46. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). Centers for Disease Control & Prevention (CDC). Updated February 16, 2021. Accessed February 21, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>
47. Ileri C, Dogan Z, Ozben B, et al. Evaluation of the relation between cardiac biomarkers and thorax computed tomography findings in COVID-19 patients. *Biomark Med*. Mar 2021;15(4):285-293. doi:10.2217/bmm-2020-0388
48. De Smet K, De Smet D, Ryckaert T, et al. Diagnostic Performance of Chest CT for SARS-CoV-2 Infection in Individuals with or without COVID-19 Symptoms. *Radiology*. Jan 2021;298(1):E30-e37. doi:10.1148/radiol.2020202708
49. Post-COVID Conditions. Centers for Disease Control & Prevention (CDC). Updated September 16, 2021. Accessed February 21, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>

## ADDITIONAL RESOURCES

1. American College of Chest Physicians. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. American College of Chest Physicians (ACCP). Updated 2017. Accessed November 19, 2021. <http://info.chestnet.org/screening-for-lung-cancer-chest-guideline-and-expert-panel-report>
2. Barman M. Acute aortic dissection. *ESC e-J Cardio Pract*. 2014;12(25):02Jul2014. doi:https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-12/Acute-aortic-dissection
3. Ceriani E, Combescure C, Le Gal G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. *J Thromb Haemost*. May 2010;8(5):957-70. doi:10.1111/j.1538-7836.2010.03801.x
4. Corrigan D, Prucnal C, Kabrhel C. Pulmonary embolism: the diagnosis, risk stratification, treatment and disposition of emergency department patients. *Clin Exp Emerg Med*. Sep 2016;3(3):117-125. doi:10.15441/ceem.16.146
5. Cohen R, Mena D, Carbajal-Mendoza R, Matos N, Karki N. Superior vena cava syndrome: A medical emergency? *Int J Angiol*. Spring 2008;17(1):43-6. doi:10.1055/s-0031-1278280

6. ~~de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Ann Intern Med.* Mar 4 2014;160(5):311-20. doi:10.7326/m13-2316~~
7. ~~Dogan D, Berk S, Gumus C, Ozdemir AK, Akkurt I. A longitudinal study on lung disease in dental technicians: what has changed after seven years? *Int J Occup Med Environ Health.* Oct 2013;26(5):693-701. doi:10.2478/s13382-013-0140-0~~
8. ~~Dyer DS, Khan AR, Mohammed TL, et al. ACR Appropriateness Criteria on chronic dyspnea: suspected pulmonary origin. *J Thorac Imaging.* May 2010;25(2):W21-3. doi:10.1097/RTI.0b013e3181d9cce4~~
9. ~~Friedman T, Quencer KB, Kishore SA, Winokur RS, Madoff DC. Malignant Venous Obstruction: Superior Vena Cava Syndrome and Beyond. *Semin Intervent Radiol.* Dec 2017;34(4):398-408. doi:10.1055/s-0037-1608863~~
10. ~~Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. *J Natl Compr Canc Netw.* Jan 1 2013;11(1):78-98. doi:10.6004/jncn.2013.0011~~
11. ~~Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J.* Nov 14 2014;35(43):3033-69, 3069a-3069k. doi:10.1093/eurheartj/ehu283~~
12. ~~Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung cancer death. *N Engl J Med.* Jul 18 2013;369(3):245-254. doi:10.1056/NEJMoa1301851~~
13. ~~Latief KH, White CS, Protopapas Z, Attar S, Krasna MJ. Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? *AJR Am J Roentgenol.* May 1997;168(5):1339-44. doi:10.2214/ajr.168.5.9129439~~
14. ~~MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology.* Jul 2017;284(1):228-243. doi:10.1148/radiol.2017161659~~
15. ~~Mazzone PJ, Silvestri GA, Patel S, et al. Screening for Lung Cancer: CHEST Guideline and Expert Panel Report. *Chest.* Apr 2018;153(4):954-985. doi:10.1016/j.chest.2018.01.016~~
16. ~~Miller A, Warshaw R, Nezamis J. Diffusing capacity and forced vital capacity in 5,003 asbestos-exposed workers: relationships to interstitial fibrosis (ILO profusion score) and pleural thickening. *Am J Ind Med.* Dec 2013;56(12):1383-93. doi:10.1002/ajim.22239~~
17. ~~Nishino M, Itoh H, Hatabu H. A practical approach to high-resolution CT of diffuse lung disease. *Eur J Radiol.* Jan 2014;83(1):6-19. doi:10.1016/j.ejrad.2012.12.028~~
18. ~~Pratter MR, Abouzgheib W, Akers S, Kass J, Bartter T. An algorithmic approach to chronic dyspnea. *Respir Med.* Jul 2011;105(7):1014-21. doi:10.1016/j.rmed.2010.12.009~~
19. ~~Pynnonen MA, Gillespie MB, Roman B, et al. Clinical Practice Guideline: Evaluation of the Neck Mass in Adults. *Otolaryngol Head Neck Surg.* Sep 2017;157(2\_suppl):S1-S30. doi:10.1177/0194599817722550~~
20. ~~Singh B, Mommer SK, Erwin PJ, Mascarenhas SS, Parsaik AK. Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism—revisited: a systematic review and meta-analysis. *Emerg Med J.* Sep 2013;30(9):701-6. doi:10.1136/emmermed.2012.201730~~

- ~~21. Tsao YC, Liu SH, Tzeng IS, Hsieh TH, Chen JY, Luo JJ. Do sanitary ceramic workers have a worse presentation of chest radiographs or pulmonary function tests than other ceramic workers? *J Formos Med Assoc.* Mar 2017;116(3):139-144. doi:10.1016/j.jfma.2016.10.017~~
- ~~22. Yang C, Liu R, Ming X, Liu N, Guan Y, Feng Y. Thoracic Organ Doses and Cancer Risk from Low Pitch Helical 4-Dimensional Computed Tomography Scans. *Biomed Res Int.* 2018;2018:8927290. doi:10.1155/2018/8927290~~
- ~~23. Yankelevitz DF, Smith JP. Understanding the core result of the National Lung Screening Trial. *N Engl J Med.* Apr 11 2013;368(15):1460-1. doi:10.1056/NEJMc1213744~~
- ~~24. Yoo SM, Lee HY, White CS. MDCT evaluation of acute aortic syndrome. *Radiol Clin North Am.* Jan 2010;48(1):67-83. doi:10.1016/j.rcl.2009.09.006~~

**Disclaimer: National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.**

#### **GENERAL INFORMATION**

- ~~It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.~~

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.